Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

P4498

Sigma-Aldrich

Pravastatin sodium salt hydrate

≥98% (HPLC), powder

Sinônimo(s):

(βR, δR,1S,2S,6S,8S,8aR)-1,2,6,7,8,8a-Hexahydro-β, δ,6-trihydroxy-2-methyl-8[(2S)-2-methyl-1-oxobutoxyl]-1-naphthaleneheptanoic acid sodium hydrate, Eptastatin sodium salt hydrate

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C23H35O7Na · xH2O
Número CAS:
81131-70-6
Peso molecular:
446.51 (anhydrous basis)
Número MDL:
MFCD00887601
Código UNSPSC:
12352200
ID de substância PubChem:
329820206
NACRES:
NA.77

fonte biológica

synthetic (organic)

Nível de qualidade

100

Ensaio

≥98% (HPLC)

Formulário

powder

cor

white

pf

171.2-173 °C

solubilidade

H2O: >10 mg/mL

originador

Bristol-Myers Squibb

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

[Na+].[H][C@@](O)(CC[C@H]1[C@@H](C)C=CC2=C[C@@H](O)C[C@H](OC(=O)[C@@H](C)CC)[C@]12[H])C[C@@H](O)CC([O-])=O

InChI

1S/C23H36O7.Na/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28;/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28);/q;+1/p-1/t13-,14-,16+,17+,18+,19-,20-,22-;/m0./s1

chave InChI

VWBQYTRBTXKKOG-IYNICTALSA-M

Informações sobre genes

human ... HMGCR(3156)

Descrição geral

Pravastatin sodium is an orally effective hypocholesterolaemic agent which is structurally similar to lovastatin and compactin.

Aplicação

Pravastatin sodium salt hydrate has been used in the enzymatic method to measure mevalonic acid in serum.

Ações bioquímicas/fisiológicas

Pravastatin sodium is a competitive, water-soluble 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.
Competitive, water-soluble 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Inhibits cholesterol synthesis in vivo (Ki ~1 nM).

Características e benefícios

This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 2

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Equipamento de proteção individual

Eyeshields, Gloves, type N95 (US)

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number
096M4760V
026M4715V
035M4712V
032M4748V
110M4707V

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Pesquise por COA

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Ashley J Bauer et al.
Hypertension (Dallas, Tex. : 1979), 61(5), 1103-1110 (2013-03-06)
Preeclampsia is a pregnancy-specific condition characterized by an imbalance of circulating angiogenic factors and new-onset hypertension. Although current treatment options are limited, recent studies suggest that pravastatin may improve angiogenic profile and reduce blood pressure in preeclampsia. We hypothesized pravastatin
Carlos S Kückelhaus et al.
Experimental parasitology, 134(1), 18-25 (2013-02-14)
The control of leishmaniases poses an important challenge due to the scarcity and toxicity of the pharmacological options available. We have previously shown that pravastatin significantly improves the course of the disease in Leishmania (L.) amazonensis-infected BALB/c mice. Since the
S M Singhvi et al.
British journal of clinical pharmacology, 29(2), 239-243 (1990-02-01)
Pravastatin sodium, a competitive inhibitor of HMG-CoA reductase, is a new orally effective hypocholesterolaemic agent. In a two-way crossover study, eight healthy male subjects each received an intravenous and an oral dose of [14C]-pravastatin sodium. The oral absorption of [14C]
Kevin F Erickson et al.
Journal of the American College of Cardiology, 61(12), 1250-1258 (2013-03-19)
The authors sought to evaluate the cost-effectiveness of statins for primary prevention of myocardial infarction (MI) and stroke in patients with chronic kidney disease (CKD). Patients with CKD have an elevated risk of MI and stroke. Although HMG Co-A reductase
Tsutomu Yamazaki et al.
International heart journal, 54(1), 33-39 (2013-02-23)
This paper describes a subanalysis of the JART Study comparing rosuvastatin and pravastatin treatment. A total of 314 subjects were analyzed in this subanalysis, 282 of whom were eligible for evaluation of the relationship between LDL-C and carotid mean-IMT change.
Exibir todos os documentos relacionados

Artigos

Cholesterol Biosynthesis Regulation

The amount of cholesterol that is synthesized in the liver is tightly regulated by dietary cholesterol levels. LDL receptors regulate the cellular transport of lipid rich low density lipoprotein (LDL) particles.

Dietary Terpenes

Terpenes comprise the largest and most diverse class of secondary metabolites; approximately 55,000 compounds have been identified to date.

Antilipemic Agents

Randomized controlled clinical studies have suggested 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are effective in both primary and secondary prevention of cardiovascular disease (CVD) events.

Conteúdo relacionado

Discover Bioactive Small Molecules for Lipid Signaling Research

Discover Bioactive Small Molecules for Lipid Signaling Research

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica